SCHEMBL3323083

SCHEMBL3323083

Cc1c(S(=O)(=O)Nc2ccc3[nH]nc(C4CCN(C)CC4)c3c2)sc2ccc(Cl)cc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 18/20 0.72
HTR1A P08908 7/20 0.57
HTR1D P28221 7/20 0.57
HTR1B P28222 7/20 0.57
HTR7 P34969 4/20 0.57
HTR2C P28335 4/20 0.57
HTR2A P28223 3/20 0.57
DRD2 P14416 3/20 0.57
ADRA1B P35368 3/20 0.57
DRD3 P35462 3/20 0.57
HTR4 Q13639 3/20 0.57
HTR2B P41595 2/20 0.57
HTR1E P28566 1/20 0.57
HTR1F P30939 1/20 0.57
NPSR1 Q6W5P4 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
DRD1 P21728 1/20 0.53
DRD4 P21917 1/20 0.53
CYP1A2 P05177 1/20 0.52
ADRB1 P08588 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3152787 0.84 HTR6 (1.00) HTR6HTR1AHTR1DHTR1BHTR7
Hydrochloric Acid SCHEMBL3147766 0.83 HTR6 (0.98) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL7195128 0.79 HTR6 (0.72) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL1460571 0.78 NPSR1 (0.60) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3147165 0.77 HTR6 (0.77) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL3147519 0.76 HTR6 (0.60) HTR6
SCHEMBL3874098 0.75 HTR6 (0.60) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6981823 0.74 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL6972216 0.74 HTR6 (0.80) HTR6HTR1AHTR1DHTR1BHTR7
SCHEMBL10239970 0.74 HTR6 (0.63) HTR6HTR1AHTR1DHTR1BHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120747-A1 COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2010-05-13 US disclosed
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-01-01 US disclosed
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments LABORATORIOS DEL DR. ESTEVE S.A. (ES) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120747-A1 COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY HTR6, AANAT, ACHE HTR6 1/4885HTR1A 11/4885HTR1D 27/4885
US-20090005417-A1 Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments HTR6, TPH2, HTR5A HTR6 1/4885HTR1A 11/4885HTR1D 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.